Device Trial Radar · NCT07927088
Halova Vaginal Ovules Versus Placebo for Genitourinary Symptoms in Premenopausal Women
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Feb 22, 2025
Primary completion
Mar 20, 2026
Study completion Jun 17, 2026
Sponsor
- Lead sponsor
- Perfect Care DistributionNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This post-market clinical study evaluated whether Halova vaginal ovules improve vaginal dryness and other genitourinary symptoms in premenopausal women and assessed their safety. The main questions were: * Does Halova reduce the severity of vaginal dryness and other bothersome genitourinary symptoms compared with placebo? * Does Halova improve vaginal health, vaginal pH, and sexual function? * What adverse events occur during treatment with Halova? * Are the treatment effects maintained after treatment is discontinued? Researchers compared Halova with placebo in a randomized, double-blind, 2:1 design. Participants: * Used Halova vaginal ovules or placebo once daily for 10 consecutive days per month, during the intermenstrual period, for 3 months * Attended study assessments at baseline, week 12, and week 24 * Were evaluated for symptoms, vaginal health, vaginal pH, sexual function, safety, and persistence of treatment effects * Completed a questionnaire on knowledge and attitudes regarding premenopause and menopause at baseline and at week 12
Conditions
- Vaginal Dryness
- Genitourinary Symptoms
Interventions
Halova vaginal ovulesDevice
Halova is a vaginal medical device formulated as ovules containing sodium hyaluronate (5 mg per ovule) and xylitol (3 mg per ovule), together with semi-synthetic glycerides, lanolin, Aloe vera oil extract, Calendula officinalis extract, colloidal silicon dioxide, and vitamin E. One ovule was administered intravaginally once daily, preferably in the evening, for 10 consecutive days per month, during the intermenstrual period, for three consecutive months.
Placebo vaginal ovulesDevice
Placebo vaginal ovules consisted of the same lipid-based excipient matrix as the investigational product, without sodium hyaluronate and xylitol. The placebo was designed to maintain blinding and was administered according to the same schedule as the active intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Most Bothersome Symptom (MBS) Score at Week 12Time frame: Baseline and Week 12
- Change From Baseline in Vaginal Health Index (VHI) Total Score at Week 12Time frame: Baseline and Week 12
- Change From Baseline in Vaginal Health Index pH Component Score at Week 12Time frame: Baseline and Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Arad County Clinical Emergency Hospital - Department of Obstetrics and Gynecology
Arad, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.